• 1-myristoylglycerophosphocholine: From Lipidomics to Assays

  2026-08-18

  Explore how 1-myristoylglycerophosphocholine, also called 14:0 Lyso-PC, can translate lipidomics findings into better fibrosis and smooth muscle assays. This guide emphasizes species-level controls, source-to-target biology, and practical reagent handling.

• Isradipine (Dynacirc): From Channels to Translation

  2026-08-17

  A mechanistic and strategic guide to using Isradipine (Dynacirc) in neurovascular, hypertension, and neurodegenerative disease research, with emphasis on channel selectivity, experimental controls, and translational interpretation.

• Pretomanid and Terminal Oxidases in Tuberculosis

  2026-08-16

  The reference study identifies the cytochrome bcc:aa3 and cytochrome bd oxidases as respiratory targets of pretomanid, clarifying how this nitroimidazole prodrug acts against both replicating and antibiotic-tolerant Mycobacterium tuberculosis. Its combination data support rational regimens using complementary terminal-oxidase inhibitors to increase bactericidal activity and limit resistance emergence.

• 7-Ethyl-10-hydroxycamptothecin: Assay Workflows

  2026-08-15

  Build reproducible colon cancer assays around 7-Ethyl-10-hydroxycamptothecin, from DMSO formulation through cell-cycle and apoptosis readouts. The workflow also incorporates SN-38-driven FUBP1–FUSE research to distinguish topoisomerase I inhibition from complementary transcriptional effects.

• Latrunculin A: Stress-Testing Actin Mechanobiology

  2026-08-15

  Latrunculin A is more than an actin-disrupting reagent: it is a reversible mechanistic probe for testing how extracellular stiffness, Piezo1 signaling, and cytoskeletal remodeling shape cellular behavior. This article outlines a translational strategy for using Latrunculin A to distinguish upstream mechanosensing from downstream actin-dependent structure and function.

• Potassium Iodide in Research Workflows

  2026-08-14

  Potassium Iodide, or KI, is a practical iodide source for controlled thyroid-protection studies, uptake assays, and formulation compatibility experiments. This guide also shows where KI fits—and does not fit—in MMP-2-responsive liposome research involving sequential PD-1 pathway blockade and IDO inhibition.

• Ciprofloxacin: Mechanism and CREC Research

  2026-08-14

  Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV. In a 2025 Guangdong study, carbapenemase-positive Enterobacter cloacae isolates showed significantly higher ciprofloxacin resistance than carbapenemase-negative isolates, supporting its use as a controlled research comparator rather than a universal treatment proxy.

• α2-adrenergic receptor agonist: Assay Strategy

  2026-08-13

  Explore how 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine can support α2-adrenergic receptor signaling research through a layered strategy that separates direct tumor effects from immune-mediated activity. The article translates recent osteosarcoma findings into practical model-selection, handling, and assay-design decisions.

• Nadolol (SQ-11725): Assay Reliability Guide

  2026-08-13

  This scenario-based guide explains how Nadolol (SQ-11725), SKU BA5097, can be incorporated into cell viability, proliferation, and cytotoxicity workflows without confusing beta-adrenergic effects with transporter-dependent exposure or assay artifacts. It combines product-handling facts with practical controls and cautiously interpreted pharmacokinetic evidence.

• A 83-01 in Breast AME Organoid Translation

  2026-08-12

  Patient-derived organoids can preserve the biology of rare breast tumors, but authenticity alone does not establish mechanism. This thought-leadership guide examines how A 83-01, a selective ALK-5 inhibitor, could be used as a disciplined TGF-β/Smad perturbation tool in adenomyoepithelioma organoid research while separating validated evidence from translational hypotheses.

• EZ Cap™ Cas9 mRNA for Neurodegeneration Studies

  2026-08-12

  EZ Cap™ Cas9 mRNA (5-moUTP) is an approximately 4548-nucleotide, Cap1-capped, polyadenylated Cas9 mRNA for guide RNA-dependent gene editing. It provides a practical research input for CRISPR-Cas9 genome editing in functional gene studies, while the cited zebrafish study defines biological targets and does not establish product-specific efficacy.

• Prochlorperazine in Melanoma: Evidence from COLO829 and C32

  2026-08-11

  The 2019 reference study examined prochlorperazine alongside perphenazine in melanotic COLO829 and amelanotic C32 melanoma cells, linking reduced viability and motility with changes in MITF and tyrosinase. Its main contribution is a phenotype-to-molecular analysis that positions a clinically familiar phenothiazine as a candidate for hypothesis-driven melanoma research, while also highlighting the limitations of extrapolating in vitro findings to treatment.

• ACSF3 Variant Links Human Height and Metabolic Rate

  2026-08-10

  The Cell Genomics study identifies rs34590044-A as an ancient regulatory variant associated with both greater human height and basal metabolic rate through increased ACSF3 expression, amino acid metabolic remodeling, and mitochondrial activity. Its combination of human genetics, functional regulatory analysis, mouse experiments, and ancient-DNA evidence provides a useful model for studying how dietary adaptation can shape coordinated physiological traits.

• PEGylated PLGA Microspheres for Extended Release

  2026-08-09

  Myers and Comolli developed and modeled PEGylated PLGA microspheres loaded with hydrocortisone 17-butyrate as a proof-of-concept platform for longer-acting intra-articular corticosteroid delivery. The study links emulsion optimization, avidin/biotin surface functionalization, and biphasic release modeling to reduced burst release and predominantly diffusion-controlled delivery over three weeks.

• TG003: A Mechanistic Guide to Clk Inhibition

  2026-08-08

  TG003 is a Cdc2-like kinase inhibitor that connects kinase selectivity with measurable changes in RNA processing. This guide explains how to interpret its biochemical, splicing, cancer, and exon-skipping applications without confusing target engagement with disease-specific efficacy.

457 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page